Author

Ronald D. Pedersen 1

1 Pfizer Inc,Collegeville, PA,United States

An update on the analysis of non-melanoma skin cancer in the tofacitinib ulcerative colitis programme

Bruce E. Sands, Millie Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

Tofacitinib for the treatment of ulcerative colitis: an update on the analysis of malignancy rates from the UC clinical programme

Gary R. Lichtenstein, Matthew A. Ciorba, Gerhard Rogler, Daniel Quirk, Andrew J. Thorpe, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Julian Panés

Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates in the tofacitinib ulcerative colitis clinical programme

Kevin L. Winthrop, Edward V. Loftus Jr., Daniel C. Baumgart, Leonardo Salese, Andrew J. Thorpe, Nervin Lawendy, Gary Chan, Ronald D. Pedersen, Walter Reinisch

Item 1 - 4 / 4
1